• 1

    Booz MK, 1972. The management of hydatid disease of bone and joint. J Bone Joint Surg Br 54 :698–709.

  • 2

    Fraiji EK Jr, DH C, 1997. Echinococcosis. Pathology of Infectious Diseases. Stamford, CT: Appleton & Lange.

  • 3

    Schaefer JW, Khan MY, 1991. Echinococcosis (hydatid disease): lessons from experience with 59 patients. Rev Infect Dis 13 :243–247.

  • 4

    Akhan O, Gumus B, Akinci D, Karcaaltincaba M, Ozmen M, 2007. Diagnosis and percutaneous treatment of soft-tissue hydatid cysts. Cardiovasc Intervent Radiol 30 :419–425.

    • Search Google Scholar
    • Export Citation
  • 5

    Junghanss T, da Silva AM, Horton J, Chiodini PL, Brunetti E, 2008. Clinical management of cystic echinococcosis: state of the art, problems, and perspectives. Am J Trop Med Hyg 79 :301–311.

    • Search Google Scholar
    • Export Citation
  • 6

    Moro P, Schantz PM, 2009. Echinococcosis: a review. Int J Infect Dis 13 :125–133.

  • 7

    Todorov T, Vutova K, Mechkov G, Petkov D, Nedelkov G, Tonchev Z, 1990. Evaluation of response to chemotherapy of human cystic echinococcosis. Br J Radiol 63 :523–531.

    • Search Google Scholar
    • Export Citation
  • 8

    Wen H, New RR, Craig PS, 1993. Diagnosis and treatment of human hydatidosis. Br J Clin Pharmacol 35 :565–574.

  • 9

    Teggi A, Lastilla MG, De Rosa F, 1993. Therapy of human hydatid disease with mebendazole and albendazole. Antimicrob Agents Chemother 37 :1679–1684.

    • Search Google Scholar
    • Export Citation
  • 10

    Horton RJ, 1997. Albendazole in treatment of human cystic echinococcosis: 12 years of experience. Acta Trop 64 :79–93.

  • 11

    Moro PL, Gonzalez AE, Gilman RH, 2000. Cystic Hydatid Disease. Hunter GW, Strickland GT, Magill AJ, eds. Hunter’s tropical medicine and emerging infectious diseases. Philadelphia: W.B. Saunders, 866–871.

  • 12

    Jung H, Hurtado M, Sanchez M, Medina MT, Sotelo J, 1992. Clinical pharmacokinetics of albendazole in patients with brain cysticercosis. J Clin Pharmacol 32 :28–31.

    • Search Google Scholar
    • Export Citation
  • 13

    Saimot AG, Meulemans A, Cremieux AC, Giovanangeli MD, Hay JM, Delaitre B, Coulaud JP, 1983. Albendazole as a potential treatment for human hydatidosis. Lancet 2 :652–656.

    • Search Google Scholar
    • Export Citation
  • 14

    Morris DL, Chinnery JB, Georgiou G, Stamatakis G, Golematis B, 1987. Penetration of albendazole sulphoxide into hydatid cysts. Gut 28 :75–80.

    • Search Google Scholar
    • Export Citation
  • 15

    Cobo F, Yarnoz C, Sesma B, Fraile P, Aizcorbe M, Trujillo R, Diaz-de-Liano A, Ciga MA, 1998. Albendazole plus praziquantel versus albendazole alone as a pre-operative treatment in intra-abdominal hydatisosis caused by Echinococcus granulosus. Trop Med Int Health 3 :462–466.

    • Search Google Scholar
    • Export Citation
  • 16

    Wilson JF, Rausch RL, McMahon BJ, Schantz PM, 1992. Parasiticidal effect of chemotherapy in alveolar hydatid disease: review of experience with mebendazole and albendazole in Alaskan Eskimos. Clin Infect Dis 15 :234–249.

    • Search Google Scholar
    • Export Citation
  • 17

    Schantz PM, 1999. Echinococcosis. Guerrant RL, Walker DH, Weller PF, eds. Tropical Infectious Diseases. New York: Churchill Livingstone, 1005–1025.

 
 
 

 

 
 
 

 

 

 

 

 

 

Intra-Cystic Drug Concentration of Albendazole Sulphoxide in Patients with Echinococcus granulosus Cysts

View More View Less
  • 1 Department of Medicine I, Division of Infectious Diseases and Tropical Medicine, Medical University of Vienna, Vienna, Austria; Institute of Tropical Medicine, University of Tübingen, Tübingen, Germany; Department of Clinical Pharmacy and Diagnostics, Faculty of Life Sciences, University of Vienna, Vienna, Austria; Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria; Karl Landsteiner Gesellschaft, Infektiologie, St. Pölten, Austria

Albendazole therapy—alone or in combination with surgery—remains the standard of care for human echinococcosis depending on the stage of disease. However, only limited data are available on target site concentrations in liver cysts and data for non-liver cysts are lacking. We report on intra-cystic concentrations of the biologically active metabolite albendazole sulphoxide in non-liver cysts indicating a relative intra-cystic drug concentration of 48–156% compared with plasma levels. These data are evidence for a satisfactory penetration of albendazole sulphoxide into Echinococcus cysts localized in other organs than the liver and underline the usefulness of albendazole therapy for this indication.

Save